Pediatric palliative care: Use of opioids for the management of pain

Pediatric Drugs

Volumn 11, Issue 2, 2009, Pages 129-151

  Zernikow, Boris ^a,b   Michel, Erik ^c   Craig, Finella ^d   Anderson, Brian J ^e  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Children's Hospital   (Germany)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CODEINE; CYCLIZINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROCODEINE; DIPYRONE; DOMPERIDONE; FENTANYL; FENTANYL CITRATE; HYDROMORPHONE; IBUPROFEN; LEVOMEPROMAZINE; LEVOMETHADONE; METHADONE; MORPHINE; NALOXONE; ONDANSETRON; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; TILIDINE; TRAMADOL; TROPISETRON;

ANALGESIA; APNEA; BRADYCARDIA; BRONCHOSPASM; BULIMIA; CHILD CARE; CLINICAL TRIAL; CONSTIPATION; DELIRIUM; DROWSINESS; DRUG DOSE ESCALATION; DRUG TOLERANCE; DRUG WITHDRAWAL; EDEMA; EUPHORIA; HALLUCINATION; HICCUP; HUMAN; HYPERALGESIA; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; MENTAL DISEASE; MYOCLONUS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PAIN; PALLIATIVE THERAPY; PATIENT CONTROLLED ANALGESIA; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RESPIRATION DEPRESSION; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; SWEATING; UNSTEADINESS; URINE RETENTION; URTICARIA; VOMITING; WORLD HEALTH ORGANIZATION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; BUPRENORPHINE; CHILD; DELAYED-ACTION PREPARATIONS; FENTANYL; HUMANS; HYDROMORPHONE; METHADONE; MORPHINE; NARCOTICS; PAIN; PALLIATIVE CARE;

EID: 62949097297     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200911020-00004     Document Type: Review

References (231)

1. Goldman A. Symptoms and suffering at the end of life in children with cancer: correspondence. N Engl J Med 2000; 342: 1997-9
2. Wolfe J, Grier HE, Klar N, et al. Symptoms and suffering at the end of life in children with cancer. N Engl J Med 2000; 342: 326-33
3. Drake R, Frost J, Collins JJ. The symptoms of dying children. J Pain Symptom Manage 2003; 26 (1): 594-603
4. WHO. Cancer pain relief and palliative care in children. Geneva: World Health Organization, 1998
5. Craig F, Abu-Saad Huijer H, Benini F, et al. IMPaCCT: standards for paediatric palliative care in Europe. Eur J Pall Care 2007; 14 (3): 109-14
6. A guide to the development of children's palliative care services: update of the report by The Association for Children with Life-threatening or Terminal Conditions and their Families and The Royal College of Paediatrics and Child Health. London: ACT and RCPCH, 2003
7. Apalliative care needs assessment for children. Dublin: Stationery Office, 2005
8. Zernikow B, Dietz B. Schmerzerkennung, -messung und -therapie bei Kindern mit kognitiver und körperlicher Behinderung. Neuropädiatrie in Klinik und Praxis 2003; 2: 12-7
9. Lenton S, Stallard P, Lewis M, et al. Prevalence and morbidity associated with non-malignant, life-threatening conditions in childhood. Child Care Health Dev 2001; 27 (389): 389-98
10. Sirkiä K, Saarinen UM, Ahlgren B, et al. Terminal care of the child with cancer at home. Acta Paediatr 1997; 86: 1125-30
11. Sirkiä K, Hovi L, Pouttu J, et al. Pain medication during terminal care of children with cancer. J Pain Symptom Manage 1998; 15: 220-6
12. Hunt A. Pain: assessment. In: Goldman A, Hain R, Liben S, editors. Oxford textbook of palliative care for children. Oxford: Oxford University Press, 2006: 281-303
13. Hicks CL, von Baeyer CL, Spafford PA, et al. The faces pain scale: revised. Toward a common metric in pediatric pain measurement. Pain 2001; 93: 173-83
14. Zernikow B, Schiessl C, Wamsler C, et al. Praktische Schmerztherapie in der pädiatrischen Onkologie. Schmerz 2006; 20: 24-39
15. Zernikow B, Smale H, Michel E, et al. Paediatric cancer pain management using the WHO analgesic ladder: results of a prospective analysis from 2265 treatment days during a quality improvement study. Eur J Pain 2006; 10: 587-95
16. Tsao JCI, Zeltzer LK. Complementary and alternative medicine approaches for pediatric pain: a review of the state-of-the-science. eCAM 2005; 2 (2): 149-59
17. Kuttner L. Pain: an integrative approach. In: Goldman A, Hain R, Liben S, editors. Oxford textbook of palliative care in children. Oxford: Oxford University Press, 2006
18. Cepeda MS, Carr DB, Lau J, et al. Music for pain relief. Cochrane Database Syst Rev 2006; 19: CD004843
19. Twycross R, Wilcock A, Charlesworth S, editors. Palliative care formulary. 2nd ed. Oxford: Radcliffe Medical Press, 2002
20. Berde CB, Sethna NF. Analgesics for the treatment of pain in children. N Engl J Med 2002; 347: 1094-103
21. Allington N, Vivegnis D, Gerard P. Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. Acta Orthop 2005; 71: 91-7
22. Stichtenoth DO, Frölich J. The second generation of COX-2 inhibitors: what advantages do the newest offer? Drugs 2003; 63 (1): 33-45
23. McNicol E, Strassels SA, Goudas L, et al. NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 2005; 25 (1): CD005180
24. Garrido MJ, Habre W, Rombout F, et al. Population pharmacokinetic/ pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res 2006; 23: 2014-23
25. Tobias JD. Tramadol for postoperative analgesia in adolescents following orthopedic surgery in a third world country. Am J Pain 1996; 6: 51-3
26. Griessinger N, Rösch W, Schott G, et al. Tramadol-Infusion zur Schmerztherapie nach groben Blaseneingriffen auf Kinderstationen. Der Urologe 1997; 36: 552-6
27. Schäffer J, Piepenbrock S, Kretz FJ, et al. Nalbuphin und Tramadol zur postoperativen Schmerzbekämpfung bei Kindern. Der Anaesthesist 1986; 35: 408-13
28. Schäffer J, Hagemann H, Holzapfel S, et al. Untersuchung zur postoperativen Schmerztherapie bei Kleinkindern mit Tramadol. Fortschritte Anästh Notfall-Intensivmed 1989; 3: 42-5
29. Erhan E, Inal MT, Aydinok Y, et al. Tramadol infusion for the pain management in sickle cell disease: a case report. Paediatr Anaesth 2007; 17: 84-6
30. Brown SC, Stinson J. Treatment of pediatric chronic pain with tramadol hydrochloride: siblings with Ehlers-Danlos syndrome - hypermobility type. Pain Res Manag 2004; 9: 209-11
31. Staritz M. Pharmacology of the sphincter of Oddi. Endoscopy 1988; 20 Suppl. 1: 171-4
32. Waldvogel HH. Analgetika Antinozizeptiva, Adjuvanzien: Handbuch für die Schmerzpraxis. Berlin: Springer Verlag, 1996
33. Stamer U, Stüber F. Pharmakogenetik und pädiatrische Schmerztherapie. Kinder Jugendmed 2004; 4: 161-7
34. Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60 (6): 636-44
35. Allgaert K, Anderson BJ, Verbesselt R, et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br J Anaesth 2005; 95: 231-9
36. Payne KA, Roelofse JA, Shipton EA. Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years: a pilot study. Anesth Prog 2002; 49: 109-12
37. Murthy B, Pandy KS, Booker PD, et al. Pharmacokinetics of tramadol in children after i.v. or caudal epidural administration. Br J Anaesth 2000; 84: 346-9
38. Anderson BJ, Meakin GH. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002; 12: 205-19
39. Williams DG, Hatch DJ, Howard RF. Codeine phosphate in paediatric medicine. Br J Anaesth 2001; 86: 413-21
40. Brousseau DC, McCarver DG, Drendel AL, et al. The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J Pediatr 2007; 150: 623-6
41. Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-95
42. Band CJ, Band PR, Deschamps M. Human pharmacokinetic study of immediate-release (codeine phosphate) and sustained-release (codeine Contin) codeine. J Clin Pharmacol 1994; 34 (14): 938-43
43. Quiding H, Olsson GL, Boreus LO, et al. Infants and young children metabolise codeine to morphine: a study after single and repeated rectal administration. Br J Clin Pharmacol 1992; 33: 45-9
44. Kamei J. Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol 1996; 102 (9): 349-59
45. Sindrup SH, Brosen K, Bjerring P, et al. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990; 48 (6): 686-93
46. Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27-33
47. Mikus G, Trausch B, Rodewald C, et al. Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin Pharmacol Ther 1997; 61: 459-66
48. Zernikow B, Schiessl C, Wamsler C, et al. Opioidtherapie chronischer Schmerzen bei Kindern: Fallbesprechungen. Der Schmerz 2005; 19: 418-25
49. Siden H, Nalewajek V. High dose opioids in pediatric palliative care. J Pain Symptom Manage 2003; 25: 397-9
50. Goldman A. The role of oral controlled-release morphine for pain relief in children with cancer. Palliat Med 1990; 4: 279-85
51. Hunt A, Joel S, Dick G, et al. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain. J Pediatr 1999; 135: 47-55
52. Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet 1997; 350: 1358-61
53. Nahata MC. Plasma concentrations of morphine in children with chronic pain: comparison of controlled release and regular morphine sulphate tablets. J Clin Pharm Ther 1991; 16: 193-5
54. Zernikow B, Lindena G. Long acting morphine for pain control in paediatric oncology. Med Pediatr Oncol 2001; 36 (4): 451-8
55. Sittl R, Richter R. Tumorschmerztherapie bei Kindern und Jugendlichen mit Morphin. Der Anaesthesist 1991; 40: 96-9
56. Hunseler C, Roth B, Pothmann R, et al. Intramuscular injections in children. Schmerz 2005; 19 (2): 140-3
57. Coffman BL, Rios GR, King CC, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997; 25: 1-4
58. Faura CC, Collins SL, Moore RA, et al. Systematic review of factors affecting the ratios of morphine and its major metabolites. Pain 1998; 74: 43-53
59. Koren G, Maurice L. Pediatric uses of opioids. Pediatr Clin North Am 1989; 36: 1141-56
60. Pacifici GM, Sawe J, Kager L, et al. Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol 1982; 22: 553-8
61. Pacifici GM, Franchi M, Giuliani L, et al. Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus. Dev Pharmacol Ther 1989; 14: 108-14
62. Kart T, Chirstrup LL, Rasmussen M. Recommended use of morphine in neonates, infants and children based on a literature review. Part 1: pharmacokinetics. Paediatr Anaesth 1997; 7 (1): 5-11
63. Lynn A, Nespeca MK, Bratton SL, et al. Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth Analg 1998; 86: 958-63
64. Van Lingen RA, Anderson BJ, Tibboel D. The effects of analgesia in the vulnerable infant during the perinatal period. Clin Perinatol 2002; 29: 511-34
65. Bouwmeester NJ, Anderson BJ, Tibboel D, et al. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br J Anaesth 2004; 92: 208-17
66. Choonara IA, McKay P, Hain R, et al. Morphine metabolism in children. Br J Clin Pharmacol 1989; 28: 599-604
67. Sjogren P, Dragstedt L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37 (8): 780-2
68. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. BMJ 1986; 232: 1548-9
69. Dagan O, Klein J, Bohn D, et al. Morphine pharmacokinetics in children following cardiac surgery: effects of disease and inotropic support. J Cardiothorac Vasc Anaesth 1993; 7: 396-8
70. McRorie TI, Lynn AM, Nespeca MK, et al. The maturation of morphine clearance and metabolism. Am J Dis Child 1992; 146: 972-6
71. Pokela ML, Olkkola KT, Seppäla T, et al. Age-related morphine kinetics in infants. Dev Pharmacol Ther 1993; 20: 26-34
72. Bhat R, Abu-Harb M, Chari G, et al. Morphine metabolism in acutely ill preterm newborn infants. J Pediatr 1992; 120: 795-9
73. Olsen GD. Morphine binding to human plasma proteins. Clin Pharmacol Ther 1975; 17: 31-5
74. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-21
75. Osborne PB, Chieng B, Christie MJ. Morphine-6 beta-glucuronide has a higher efficacy than morphine as a mu-opioid receptor agonist in the rat locus coeruleus. Br J Pharmacol 2000; 131 (7): 1422-8
76. Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. J Clin Pharmacol 2002; 42 (5): 569-76
77. Thompson PI, Joel SP, John L, et al. Respiratory depression following morphine and morphine-6-glucuronide in normal subjects. Br J Clin Pharmacol 1995; 40: 145-52
78. Gong QL, Hedner T, Bjorkman R, et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249-55
79. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579-85
80. Barrett DA, Barker DP, Rutter N, et al. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions. Br J Clin Pharmacol 1996; 41: 531-7
81. Collins JJ, Geake J, Grier HE, et al. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. J Pediatr 1996; 129 (5): 722-8
82. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage 2005; 29: 57-66
83. Babul N, Darke AC, Hain R. Hydromorphone and metabolite pharmacokinetics in children. J Pain Symptom Manage 1995; 10: 335-7
84. Drake R, Longworth J, Collins JJ. Opioid rotation in children with cancer. J Pall Med 2004; 7: 419-22
85. Cone EJ, Phelps BA, Gorodetzky CW. Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs, and rabbits. J Pharm Sci 1977; 66: 1709-13
86. Babul N. Putative role of hydromorphone metabolites in myoclonus [published erratum appears in Pain 1993; 52: 123]. Pain 1992; 51: 260-1
87. Hagen N, Thirlwell MP, Dhaliwal HS, et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995; 35: 37-44
88. Lindena G, Arnau H, Liefhold J. Hydromorphon: pharmakologische Eigenschaften und therapeutische Wirksamkeit. Schmerz 1998; 12: 195-204
89. Boulton DW, Arnaud P, DeVane CL. Phamacokinetics and pharmacodynamics of methadone enantiomers after a single dose of racemate. Clin Pharmacol Ther 2001; 70: 48-57
90. Gourlay GK, Wilson PR, Glynn CJ. Pharmacodynamics and pharmacokinetics of methadone during the perioperative period. Anesthesiology 1982; 57: 458-67
91. Sabatowski R, Kasper SM, Radbruch L. Patient-controlled analgesia with intravenous L-methadone in a child with cancer pain refractory to high-dose morphine. J Pain Symptom Manage 2002; 23: 3-5
92. Berde CB, Holzman RS, Sethna NF. A comparison of methadone and morphine for postoperative analgesia in children and adolescents [abstract]. Anesthesiology 1988; 69 Suppl. 3A: A768
93. Berde CB, Beyer JE, Boumaki MC, et al. Comparison of morphine and methadone for prevention of postoperative pain in 3- to 7-year-old children. J Pediatr 1991; 119 (1): 136-41
94. Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33 (4): 485-518
95. Chana SK, Anand KJ. Can we use methadone for analgesia in neonates? Arch Dis Child Fetal Neonatal Ed 2001; 85 (2): F79-81
96. Martinson IM, Nixon S, YaDeau R, et al. Nursing care in childhood cancer: methadone. Am J Nurs 1982; 82: 432-5
97. Miser AW, Miser JS. The use of oral methadone to control moderate and severe pain in children and young adults with malignancy. Clin J Pain 1986; 1: 243-8
98. Bruera E, Palmer JL, Rico MA, et al. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 2004; 22 (1): 185-92
99. Borland M, Jacobs I, King B, et al. A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department. Ann Emerg Med 2007; 49: 335-40
100. Mayes S, Ferrone M. Fentanyl HCI patient-controlled iontophoretic transdermal system for the management of acute postoperative pain. Ann Pharmacother 2006; 40 (12): 2178-86
101. Zernikow B, Michel E, Anderson BJ. Transdermal fentanyl in childhood and adolescence: a comprehensive literature review. J Pain 2007; 8: 187-207
102. Christensen ML, Wang WC, Harris S, et al. Transdermal fentanyl administration in children and adolescents with sickle cell pain crisis. Hematol Oncol 1996; 18: 372-6
103. Paut O, Camboulives J, Viard L, et al. Pharmacokinetics of transdermal fentanyl in the peri-operative period in young children. Anaesthesia 2000; 5: 1202-7
104. Levron JC. Pharmacokinetic: de la Recherche a la Clinique. In: Bres J, Panis G, editors. A special issue of the intern. In J Clin Pharm 1992; 199-203
105. Collins JJ, Dunkel IJ, Gupta SK, et al. Transdermal fentanyl in children with cancer pain: feasibility, tolerability and pharmacokinetic correlates. J Pediatr 1999; 134: 319-23
106. Finkel JC, Finley A, Greco C, et al. Transdermal fentanyl in the management of children with chronic severe pain: results from an international study. Cancer 2005; 104 (12): 2847-57
107. Hunt A, Goldman A, Devine T, et al. Transdermal fentanyl for pain relief in a paediatric palliative care population. Palliat Med 2001; 15: 405-12
108. Irving H, Myles J, Thompson A, et al. The use of transdermal fentanyl in adolescent palliative patients: a single-centre experience [abstract]. 4th Congress of the European Association of Palliative Care; 1995 Dec 6-9; Barcelona
109. Noyes M, Irvin H. The use of transdermal fentanyl in pediatric oncology palliative care. Am J Hosp Palliat Care 2001; 18: 411-6
110. Tobias JD. Transdermal fentanyl: applications and indications in the pediatric patient. Am J Pain Manag 1992; 2: 30-3
111. Mannerkoski MK, Heiskala HJ, Santavauori PR, et al. Transdermal fentanyl therapy for pains in children with infantile neuronal ceroid lipofuscinosis. Eur J Paediatr Neurol 2001; 5 Suppl. A: 175-7
112. Patt RB, Lustik S, Litman RS. The use of transdermal fentanyl in a six-year-old patient with neuroblastoma and diffuse abdominal pain. J Pain Symptom Manage 1993; 8: 317-9
113. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25: 1072-80
114. Sasson M, Shvartzman P. Fentanyl patch sufficient analgesia for only one day. J Pain Symptom Manage 2006; 31: 389-90
115. Marier JF, Lor M, Potvin D, et al. Pharmacokinetics, tolerability and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 2006; 46: 642-53
116. Sathyan G, Guo C, Sivakumar K, et al. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin 2005; 21: 1961-8
117. Johnson KL, Erickson JP, Holley FO. Fentanyl pharmacokinetics in the paediatric population [abstract]. Anesthesiology 1984; 61 (3 Suppl. A): A441
118. Robert R, Brack A, Blakeney P, et al. A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing. J Burn Care Rehabil 2003; 24 (6): 351-5
119. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79: 303-12
120. Streisand JB, Busch MA, Egan TD, et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anaesthesia 1998; 88 (2): 305-9
121. Dsida RM, Wheeler M, Birmingham PK, et al. Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. Anesth Analg 1998; 86 (1): 66-70
122. Wheeler M, Birmingham PK, Dsida RM, et al. Uptake pharmacokinetics of the Fentanyl Oralet® in children scheduled for central venous access removal: implications for the timing of initiating painful procedures. Paediatr Anaesth 2002; 12: 594-9
123. Inturrisi CE, Colburn WA. Application of pharmacokinetic-pharmacodynamic modeling to analgesia. In: Foley KM, Inturrisi CE, editors. Advances in pain research and therapy: opioid analgesics in the management of clinical pain. New York: Raven Press, 1986: 441-52
124. Lichtor JL, Sevarino FB, Joshi GP, et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 1999; 89 (3): 732-8
125. Lee M, Kern SE, Kisicki JC, et al. A pharmacokinetic study to compare two simultaneous 400 mg doses with a single 800 mg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2003; 26 (2): 743-7
126. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29: 297-326
127. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 1985; 57: 192-6
128. Olkkola KT, Manuksela EL, Korpela R. Pharmacokinetics of intravenous buprenorphine in children. Br J Clin Pharmacol 1989; 28: 202-4
129. Kamal RS, Khan M. Caudal analgesia with buprenorphine for postoperative pain relief in children. Paediatr Anaesth 1995; 5: 101-6
130. Manuksela EL, Korpela R, Olkkola KT. Comparison of buprenorphine with morphine in the treatment of postoperative pain in children. Anesth Analg 1988; 67: 233-9
131. Gangopadhyay AN, Bhattacharya P, Sinha A. Caudal epidural buprenorphine for postoperative pain relief in children. Pediatr Surg Int 1992; 7: 124-5
132. Lone AQ, Naquash I, Qazi S. Role of buprenorphine hydrochloride in attenuating the haemodyanamic, hormonal and metabolic responses to surgery in children. JK-Practitioner 1998; 5: 300-2
133. Massimo L. Control of pain with sublingual buprenorphine in children with cancer [abstract]. J Pediatr Hematol Oncol 1985; 3: 224
134. Girotra S, Kumar S, Rajendran KM. Comparison of caudal morphine and buprenorphine for post-operative analgesia in children. Eur J Anaesthesiol 1993; 10: 309-12
135. Girotra S, Kumar S, Rajendran KM. Postoperative analgesia in children who have genito-urinary surgery: a comparison between caudal buprenorphine and bupivacaine. Anaesthesia 1990; 45: 406-8
136. Geib AJ, Babu K, Ewald MB. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics 2006; 118: 1746-51
137. Gaulier JM, Charvier F, Monceaux F, et al. Ingestion of high-dose buprenorphine by a 4 year-old child. J Clin Toxicol 2004; 42: 993-5
138. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract Suppl 2003; 133: 9-14
139. Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2003; 25: 150-68
140. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 2006; 28 (6): 943-52
141. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice: a post-marketing surveillance study in 13179 patients. Curr Med Res Opin 2005; 21: 1147-56
142. Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63 (19): 1999-2010
143. Cuer JC, Dapoigny M, Larpent JL, et al. Effects of buprenorphine on motor activity of the sphincter of Oddi in man. Eur J Clin Pharmacol 1989; 36: 203-4
144. Michel E, Zernikow B. Buprenorphineinsatz bei Kindern. Eine klinischpharmakologische Übersicht. Monatsschr Kinderheilkd 2006; 154: 799-807
145. Picard N, Cresteil T, Djebli N. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 2005; 33: 689-95
146. Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37: 17-40
147. Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. J Pall Med 2006; 20 (1): 17-23
148. Olkkola KT, Hamunen K, Manuksela EL. Clinical pharmacokinetics and pharmacodynamics of opioid analgesics in infants and children. Clin Pharmacokinet 1995; 28: 385-404
149. Barrett DA, Simpson J, Rutter N, et al. The pharmacokinetics and physiological effects of buprenorphine infusion in premature neonates. Br J Clin Pharmacol 1993; 36 (3): 215-9
150. Koppert W, Ihmsen H, Kordy H. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118: 15-22
151. Likar R, Sittl R. Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies. Anesth Analg 2005; 100: 781-5
152. Staats PS, Johnson RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Progr Anesthesiol 2002; 16: 235-49
153. Lufty K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol 2004; 2: 395-402
154. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006; 20 Suppl. 1: 3-8
155. Cowan A. Buprenorphine: new pharmacological aspects. Int J Clin Pract Suppl 2003; 133: 3-8
156. Ohtani M, Kotaki H, Nishitateno K. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281 (1): 428-33
157. Ohtani M, Kotaki H, Sawada Y. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic- pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272: 505-10
158. Kokki H, Rasanen I, Lasalmi M, et al. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children. Clin Pharmacokinet 2006; 45 (7): 745-54
159. Poyhiä R, Seppäla T, Olkkola KT, et al. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617-21
160. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80: 296-302
161. Takala A, Kaasalainen V, Seppala T, et al. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone. Acta Anaesthesiol Scand 1997; 41: 309-12
162. Olkkola KT, Hamunen K, Seppäla T, et al. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38: 71-6
163. Pokela ML, Anttilla E, Seppäla T, et al. Marked variation in oxycodone pharmacokinetics in infants. Paediatr Anaesth 2005; 15: 560-5
164. Sharar SR, Garrougher MN, Selzer K, et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2000; 23: 27-31
165. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95 (4): 434-41
166. Drake R, Hain R. Pain: pharmacological management. In: Goldman A, Hain R, Liben S, editors. Oxford textbook of palliative care for children. New York: Oxford Universitiy Press, 2006: 304-31
167. Friedrichsdorf SJ, Finney D, Bergin M, et al. Breakthrough pain in children with cancer. J Pain Symptom Manage 2007; 32 (2): 209-16
168. Flogegard H, Ljungman G. Characteristics and adequacy of intravenous morphine infusions in children in a paediatric oncology setting. Med Pediatr Oncol 2003; 40: 233-8
169. Tazeroualti N, De Groote F, De Hert S, et al. Oral clonidine vs midazolam in the prevention of sevoflurane-induced agitation in children: a prospective, randomized, controlled trial. Br J Anaesth 2007; 98: 667-71
170. Morley JS, Watt JW, Wells JC, et al. Methadone in pain uncontrolled by morphine [abstract]. Lancet 1993; 342 (8881): 1243
171. Morley JS, Makin MK. Comments on Ripamonti, et al. Pain 1997; 70 (1997): 109-15
172. Tobias JD. Pain management for the critically ill child in the pediatric intense care unit. In: Schlechter NL, Berde CB, Yaster M, editors. Pain in infants, children, and adolescents. Philadelphia (PA): Lippincott Williams & Wilkins, 2003: 807-40
173. Nauck F, Ostgathe C, Dickerson ED. A German model for methadone conversion. Am J Hosp Palliat Care 2001; 18: 200-2
174. Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216-21
175. Mercadante S, Ferrera P, Villari P, et al. Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 2005; 23 (22): 5229-34
176. Collins JJ, Grier HE, Kinney HC, et al. Control of severe pain in children with terminal malignancy. J Pediatr 1995; 126: 653-7
177. Miser AW, Davis DM, Hughes CS. Continuous subcutaneous infusion of morphine in children with cancer. Am J Dis Child 1983; 137: 383-5
178. Miser AW, Miser JS, Clark C. Continuous intravenous infusion of morphine sulfate for control of severe pain in children with terminal malignancy. J Pediatr 1980; 96: 930-2
179. Collins JJ, Berde CB, Grier HE, et al. Massive opioid resistance in an infant with a localized metastasis to the midbrain periaqueductal gray. Pain 1995; 63: 271-5
180. Koppert W, Schmelz M. The impact of opioid-induced hyperalgesia for postoperative pain. Best Pract Res Clin Anaesthesiol 2007; 21: 65-83
181. Angst MS, Clark JD. Opioid-induced hyperalgesia. Anesthesiology 2006; 104: 570-87
182. Heger S, Maier C, Otter K, et al. Morphine induced allodynia in a child with brain tumour. BMJ 1999; 319 (7210): 627-9
183. Marples IL, Murray P. Morphine induced allodynia in child with brain tumour: signs are more likely to have been due to underlying medical condition [letter]. BMJ 2000; 320 (7231): 381
184. Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000; 27: 524-8
185. Zernikow B. Schmerztherapie bei Kindern. Heidelberg: Springer Verlag, 2005
186. Zernikow B, Bauer A, Andler W. Schmerztherapie in der pädiatrischen Onkologie: Eine Bestandsaufnahme. Schmerz 2001; 16: 140-9
187. Maxwell LG, Kaufmann SC, Bitzer S, et al. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg 2005; 100: 953-8
188. Cepeda MS, Africano JM, Manrique AM, et al. The combination of low dose of naloxone and morphine in PCA does not decrease opioid requirements in the postoperative period. Pain 2002; 96: 73-9
189. Cepeda MS, Alvarez H, Morales H, et al. Addition of ultralow dose naloxone to postoperative morphine PCA: unchanged analgesia and opioid requirement but decreased incidence of opioid side effects. Pain 2004; 107: 41-6
190. Cheung CL, van Dijk M, Green JW, et al. Effects of low-dose naloxone on opioid therapy in pediatric patients: a retrospective case-control study. I. Intensive Care Med 2007; 33: 190-4
191. Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006; 20 Suppl. 1: s3-8
192. Johnson RE, Fudala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage 2005; 29 (3): 297-326
193. Yee JD, Berde CB. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994; 9 (2): 122-5
194. Hullett BJ, Chambers NA, Pascoe EM, et al. Tramadol vs morphine during adenotonsillectomy for obstructive sleep apnea in children. Paediatr Anaesth 2006; 16: 648-53
195. Tobias JD. Seizure after overdose of tramadol. South Med J 1997; 90: 826-7
196. Marsh DF, Hatch DJ, Fitzgerald M. Opioid systems and the newborn. Br J Anaesth 1997; 79: 787-95
197. Purcell-Jones G, Dormon MB, Summer BM. The use of opioids in neonates: a retrospective study of 933 cases. Anaesthesia 1987; 42: 1316-20
198. Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410-22
199. Voronov P, Przybylo HJ, Jagannathan N. Apnea in a child after oral codeine: a genetic variant: an ultra-rapid metabolizer. Paediatr Anaesth 2007; 17: 684-7
200. Magnani B, Evans R, Hegland UG, et al. Codeine intoxication in the neonate. Pediatrics 1999; 104: e75
201. Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368 (9536): 704
202. Thwaites D, McCann S, Broderick P. Hydromorphone neuroexcitation. J Pall Med 2004; 7: 545-50
203. Wright AW, Nocente ML, Smith MT. Hydromorphone-3-glucuronide: biochemical synthesis and preliminary pharmacological evaluation. Life Sci 1998; 63: 401-11
204. Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001; 69 (4): 409-20
205. Karir V. Bradycardia associated with intravenous methadone administered for sedation in a patient with acute respiratory distress syndrome. Pharmacotherapy 2002; 22: 1196-9
206. Wheeler AD, Tobias JD. Bradycardia during methadone therapy in an infant. Pediatr Crit Care Med 2006; 7: 83-5
207. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother 2005; 19 (4): 13-24
208. Friesen RH, Carpenter E, Madigan CK, et al. Oral transmucosal fentanyl citrate for preanaesthetic medication of paediatric cardiac surgery patients. Paediatr Anaesth 1995; 5: 29-33
209. Goldstein-Dresner MC, Davis PJ, Kretchman E, et al. Double-blind comparison of oral transmucosal fentanyl citrate with oral meperidine, diazepam, and atropine as preanesthetic medication in children with congenital heart disease. Anesthesiology 1991; 74 (1): 28-33
210. Epstein RH, Mendel HG, Witkowski TA, et al. The safety and efficacy of oral transmucosal fentanyl citrate for preoperative sedation in young children. Anesth Analg 1996; 83 (6): 1200-5
211. Feld LH, Champeau MW, van Steenis CA, et al. Preanesthetic medication in children: a comparison of oral transmucosal fentanyl citrate versus placebo. Anesthesiology 1989; 71 (3): 374-7
212. Klein EJ, Diekema DS, Paris CA, et al. A randomized, clinical trial of oral midazolam plus placebo versus oral midazolam plus oral transmucosal fentanyl for sedation during laceration repair. Pediatrics 2002; 109 (5): 894-7
213. Schlechter NL, Weisman SJ, Rosenblum M, et al. The use of oral transmucosal fentanyl citrate for painful procedures in children. Paediatr Anaesth 1995; 5: 29-33
214. Howell TK, Smith S, Rushman SC, et al. A comparison of oral transmucosal fentanyl and oral midazolam for premedication in children. Anaesthesia 2002; 57 (8): 798-805
215. Sharar SR, Bratton SL, Garrougher MN, et al. A comparison of oral transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil 1998; 19: 516-21
216. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006; 96: 627-32
217. Hamunen K, Olkkola KT, Maunuksela EL. Comparison of the ventilatory effects of morphine and buprenorphine in children. Acta Anaesthesiol Scand 1993; 37: 449-53
218. Zanette G, Manani G, Giusti F, et al. Respiratory depression following administration of low dose buprenorphine as postoperative analgesic after fentanyl balanced anaesthesia. Paediatr Anaesth 1996; 6: 419-22
219. Zola EM, McLeod DC. Comparative effects and analgesic efficacy of the agonist-antagonist opioids. Clin Pharmacol 1983; 17: 411-7
220. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 1989; 45: 66-71
221. Rodgers BM, Webb CJ, Stergios D, et al. Patient controlled analgesia in pediatric surgery. J Pediatr Surg 1988; 23: 59-62
222. Melzer-Lange MD, Walsh-Kelly CM, Lea G. Patient-controlled analgesia for sickle cell pain crisis in a pediatric emergency department. Pediatr Emerg Care 2004; 20: 2-4
223. Gaukroger PB, Chapman MJ, Davey RB. Pain control in paediatric burns: the use of patient-controlled analgesia. Burns 1991; 17: 396-9
224. Trentadue NO, Kachoyeanos MK, Lea G. A comparison of two regimens of patient-controlled analgesia for children with sickle cell disease. J Pediatr Nurs 1998; 13: 15-9
225. Mackie AM, Coda BC, Hill HF. Adolescents use patient-controlled analgesia effectively for relief from prolonged oropharyngeal mucositis pain. Pain 1991; 46: 265-9
226. Dunbar PJ, Buckley P, Gavrin JR, et al. Use of patient-controlled analgesia for pain control for children receiving bone marrow transplant. J Pain Symptom Manage 1995; 10: 604-11
227. Collins JJ, Geake J, Grier HE, et al. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone. J Pediatr 1996; 129 (5): 722-8
228. Anghelescu DL, Burgoyne LL, Oakes LL, et al. The safety of patient-controlled analgesia by proxy in pediatric oncology patients. Anesth Analg 2005; 101: 1623-7
229. Walder B, Schafer M, Henzi I, et al. Efficacy and safety of patient-controlled opioid analgesia for acute postoperative pain: a quantitative systematic review. Acta Anaesthesiol Scand 2001; 45: 795-804
230. Schiessl C, Gravou C, Zernikow B, et al. Use of patient-controlled analgesia for pain control in dying children. Support Care Cancer 2008; 16 (5): 531-6
231. Doyle E, Morton NS, McNicol LR. Comparison of patient-controlled analgesia in children by IV and SC routes of administration. Br J Anaesth 1994; 72: 533-6